The FDA is requiring a new vision loss warning on every GLP-1 drug on the market, including Ozempic, Wegovy, Mounjaro and Zepbound, after concluding the medications carry a potential increased risk of a rare eye condition that can cause sudden, permanent blindness in one eye. The agency announced the change Monday.
The condition is called NAION, short for non-arteritic anterior ischemic optic neuropathy. In plain terms, it happens when blood flow to the optic nerve, the cable that carries what your eye sees to your brain, suddenly drops. Without enough blood, the nerve gets damaged, and the vision it controls can be lost for good. It usually hits one eye, it is usually painless, and people often notice it when they wake up.
GLP-1 drugs are the shots and pills that mimic a natural hormone to lower blood sugar and curb appetite. They started as diabetes treatments and became the biggest weight loss drugs in the world. The new warning covers all of them: Ozempic, Wegovy and Rybelsus from Novo Nordisk, Mounjaro and Zepbound from Eli Lilly, Lilly’s new weight loss pill Foundayo, plus older drugs like Victoza, Saxenda and Trulicity. Every one of these products has had NAION cases reported since hitting the market, according to the FDA.
Drugmakers now have to add the vision loss warning to the Warnings and Precautions section of their labels, the part of the paperwork doctors rely on to understand a drug’s most serious risks.
The FDA started looking into this after a July 2024 study out of Massachusetts Eye and Ear found that patients on semaglutide, the active ingredient in Ozempic and Wegovy, were more likely to be diagnosed with NAION. People with type 2 diabetes on the drug had about four times the risk, and people taking it for weight had about seven times the risk, compared with people on other medications. The FDA said that study had limits but was enough to dig deeper.
The agency then reviewed 126 clinical trials involving more than 134,000 patients. Among people taking GLP-1 drugs, there were 6.4 NAION cases for every 100,000 people a year. Among people on a placebo or other diabetes medications, there were 3.8. A review of real world data from patients with type 2 diabetes who started these drugs between 2019 and 2024 also found a higher risk compared with people who started another common class of diabetes pills.
Those numbers show how rare this still is. Most people on these drugs will never develop NAION. But the FDA found the same signal showing up across trials, real world records and published studies, which is why the agency decided a vision loss warning belongs on the label. The FDA is describing it as a potential increased risk, not a proven cause, and it said animal studies have not explained how the drugs would trigger it.
Made to order and shipped to your door.
Europe got there first, but only partly. In June 2025, European regulators concluded NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 users, and updated those labels. The FDA’s action goes further by covering every GLP-1 drug, not just semaglutide.
The warning signs are what matter most for anyone taking these medications. The FDA is telling patients to report right away any sudden loss of vision in one eye, blurry or missing spots in what they see, colors that look washed out or off, or central vision that is suddenly less sharp. Doctors are being told to send patients with those symptoms to an eye specialist quickly.
If NAION is confirmed, the FDA says doctors should consider taking the patient off the GLP-1 drug unless the benefits clearly outweigh the risk. That decision goes through the prescriber. Many people take these drugs for diabetes, heart protection, kidney disease or sleep apnea, and stopping can carry its own dangers.
The FDA also flagged two groups who need to be especially careful. People who have already had NAION face a higher chance of it happening again, and someone who loses vision in one eye is at greater risk of losing it in the other.
Millions of Americans are on these drugs, and prescriptions keep climbing. Even a small increase in risk can mean more people walking into eye clinics with vision they cannot get back, which is why the FDA wants every patient to know the warning signs before anything happens.
